Welcome to our dedicated page for Liveworld news (Ticker: LVWD), a resource for investors and traders seeking the latest updates and insights on Liveworld stock.
LiveWorld, Inc. (OTC Markets: LVWD) is a social-first digital agency and software company that regularly publishes detailed business and financial updates. The LVWD news feed features company-issued announcements that explain how LiveWorld combines social media engagement, compliance, and insight solutions with software and AI, with a particular focus on healthcare and pharmaceutical brands.
Investors and observers following LVWD news will find recurring quarterly and annual financial results, including condensed balance sheets, statements of operations, and cash flow statements. These releases highlight revenue trends, operating expenses, net income or loss, and cash and cash equivalents, providing insight into how LiveWorld’s social-first and AI-focused strategy aligns with its financial performance.
Beyond earnings, LiveWorld’s news includes updates on its AI initiatives, such as an AI strategic roadmap, increased investment in AI enablement across the agency, and the launch of AI-powered products. The company has announced AI Brand Reputation Indexes for pharmaceutical and over-the-counter consumer healthcare brands, describing how large language models and AI platforms shape brand perception.
Additional LVWD news items cover developments in healthcare and pharma marketing, new solution sets in areas like compliance support for digital and social media, and changes to the company’s board of directors that are tied to its AI and healthcare growth strategy. For anyone researching LiveWorld’s evolving role in social media–driven customer relationships, this news page offers a centralized view of the company’s financial disclosures, strategic direction, and AI-related projects.
LiveWorld (LVWD) reported Q3 2024 financial results showing significant growth. Total revenues reached $3.1 million, up 13% year-over-year, with healthcare revenues growing 17% to $2.6 million. Net income from operations improved to $291,000, a substantial increase from $46,000 in Q3 2023. Cash position strengthened to $6.2 million, up $1.5 million from December 2023. The company expects 15-20% revenue growth in H2 2024 compared to H1. Despite facing corporate marketing budget constraints and client attrition, LiveWorld has offset these challenges with new client acquisitions and existing client growth.
LiveWorld, Inc. (OTC Markets: LVWD) and Sermo have released findings from a survey of 317 US physicians across ten therapeutic categories, confirming the significant influence of Key Opinion Leaders (KOLs) and Digital Opinion Leaders (DOLs) on Healthcare Providers' (HCPs) prescribing behavior. Key findings include:
- 60% of HCPs changed perceptions of medications based on influencer social media content
- 50% changed prescriptions due to influencer content
- 69% engage with influencer content daily
The survey highlights preferences for platforms like Sermo, Instagram, and LinkedIn, with content types such as Q&A sessions and case studies being most engaging. Credibility factors for influencers include credentials, peer endorsements, and evidence-based content. The study also provides insights into generational and specialty-specific preferences, emphasizing the shift in medical information dissemination in the digital age.
LiveWorld, Inc. (OTC: LVWD) reported its Q2 2024 financial results, showing a decrease in revenues and a net loss from operations. Key highlights include:
- Total revenues of $2.8 million, down 9% year-over-year
- Healthcare revenues of $2.4 million
- Net loss from operations of ($134,000)
- Cash increased by $136,000 to $4.8 million
The company expects flat revenues for 2024 compared to 2023 due to tightened corporate budgets and client program attrition. LiveWorld is investing in new solutions and market segments, aiming for future growth in 2025 and beyond.
LiveWorld (OTC Markets: LVWD) announced its financial results for Q1 2024, reporting total revenues of $2.6 million, a 6% decrease from the same period in 2023. Healthcare revenues accounted for $2.3 million. The company recorded a net loss of $498,000, compared to a net income of $134,000 in Q1 2023. Cash reserves decreased by $320,000 to $4.3 million. The company added pharma executives Helen Chang and Jennifer Sherak to its board and published a business report detailing its growth strategy. Management expects reduced losses and increased revenue in the upcoming quarters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.